Document ID: chunk:federal_register_of_legislation:F2024L01024:front:0:p92
Version: federal_register_of_legislation:F2024L01024
Segment Type: other
Provision Reference: 
Character Range: 261511–264508

19. Coxiella burnetii;
20. Rickettsia prowazekii;
1. C. 351. d. "Toxins", as follows, and "sub‑unit of toxins" thereof:
1. Botulinum toxins;
2. Clostridium perfringens alpha, beta 1, beta 2, epsilon and iota toxins;
3. Conotoxins;
4. Ricin (CAS 9009‑86‑3);
5. Saxitoxin (CAS 35523‑89‑8);
6. Shiga toxins (shiga‑like toxins, verotoxins, and verocytotoxins);
7. Staphylococcus aureus enterotoxins, hemolysin alpha toxin, and toxic shock syndrome toxin (formerly known as Staphylococcus enterotoxin F);
8. Tetrodotoxin;
9. Not used since 2022;
10. Microcystins (Cyanoginosins);
11. Aflatoxins;
12. Abrin;
13. Not used since 2022;
14. Diacetoxyscirpenol toxin;
1. C. 351. d. 15. T‑2 toxin;
16. HT‑2 toxin;
17. Modeccin;
18. Volkensin;
19. Viscum Album Lectin 1 (Viscumin);
20. Brevetoxins;
21. Gonyautoxins;
22. Nodularins;
23. Palytoxin;
Note 1: 1C351.d does not apply to "immunotoxins".
Note 2: 1C351.d. does not apply to botulinum toxins or conotoxins in product form meeting all of the following criteria:
a. Are pharmaceutical formulations designed for human administration in the treatment of medical conditions;
b. Are pre‑packaged for distribution as medical products;
c. Are authorised by a state authority to be marketed as medical products.
e. Fungi, whether natural, enhanced or modified, either in the form of "isolated live cultures" or as material including living material which has been deliberately inoculated or contaminated with such cultures, as follows:
1. Coccidioides immitis;
2. Coccidioides posadasii.
Note: 1C351 does not apply to "vaccines" or "immunotoxins".
1. C. 352. Animal pathogens, as follows:
a. Viruses, whether natural, enhanced or modified, either in the form of "isolated live cultures" or as material including living material which has been deliberately inoculated or contaminated with such cultures, as follows:
1. African swine fever virus;
2. Avian influenza virus, which are:
a. Uncharacterised; or
b. Defined in Annex I(2) EC Directive 2005/94/EC (O.J. L.10 14.1.2006 p.16) as having high pathogenicity, as follows:
1. Type A viruses with an IVPI (intravenous pathogenicity index) in 6 week old chickens of greater than 1.2; or
2. Type A viruses of the subtypes H5 or H7 with genome sequences codified for multiple basic amino acids at the cleavage site of the haemagglutinin molecule similar to that observed for other HPAI viruses, indicating that the haemagglutinin molecule can be cleaved by a host ubiquitous protease;
1. C. 352. a. 3. Bluetongue virus;
4. Foot‑and‑mouth disease virus;
5. Goatpox virus;
6. Herpes virus (Aujeszky's disease);
7. Swine fever virus (Hog cholera virus);
8. Rabies virus and all other members of the Lyssavirus genus;
9. Newcastle disease virus;
10. Peste‑des‑petits ruminants virus;
11. Porcine Teschovirus;
12. Rinderpest virus;
13. Sheeppox virus;
14. Teschen disease virus;
15. Vesicular stomatitis virus;
16. Lumpy skin disease virus;
17. African horse sickness virus;
18. Swine vesicular disease virus.
1. C. 352.